Last reviewed · How we verify
oxaliplatin , fluorouracil, and leucovorin
oxaliplatin , fluorouracil, and leucovorin is a Platinum-based chemotherapeutic agent and thymidylate synthase inhibitor Small molecule drug developed by Sun Yat-sen University. It is currently in Phase 3 development for Adjuvant treatment of stage III colon cancer, First-line treatment of metastatic colorectal cancer.
Oxaliplatin, fluorouracil, and leucovorin work together to inhibit thymidylate synthase and DNA synthesis, leading to cell death in rapidly dividing cancer cells.
Oxaliplatin, fluorouracil, and leucovorin work together to inhibit thymidylate synthase and DNA synthesis, leading to cell death in rapidly dividing cancer cells. Used for Adjuvant treatment of stage III colon cancer, First-line treatment of metastatic colorectal cancer.
At a glance
| Generic name | oxaliplatin , fluorouracil, and leucovorin |
|---|---|
| Sponsor | Sun Yat-sen University |
| Drug class | Platinum-based chemotherapeutic agent and thymidylate synthase inhibitor |
| Target | Thymidylate synthase |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Fluorouracil is a thymidylate synthase inhibitor that blocks the production of thymidine, a nucleotide required for DNA synthesis. Leucovorin is a folate analog that helps to stabilize the complex formed between fluorouracil and thymidylate synthase, increasing the effectiveness of fluorouracil. Oxaliplatin is a platinum-based chemotherapeutic agent that forms platinum-DNA adducts, leading to DNA damage and cell death.
Approved indications
- Adjuvant treatment of stage III colon cancer
- First-line treatment of metastatic colorectal cancer
Common side effects
- Neutropenia
- Diarrhea
- Nausea and vomiting
- Fatigue
- Anemia
Key clinical trials
- A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care in Participants With Non-MSI-H/dMMR, PD-L1 Positive Advanced Colorectal Cancer (PHASE2)
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial (PHASE2)
- Individual Response to Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Treatment of Peritoneal Carcinomatosis From Peritoneal Mesothelioma or Atypical Mesothelial Proliferation or From Ovarian, Colorectal, or Appendiceal Histologies (PHASE1)
- Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT Study (PHASE3)
- Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial) (PHASE2)
- Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer (PHASE1)
- A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (PHASE2)
- Oxaliplatin, Leucovorin, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- oxaliplatin , fluorouracil, and leucovorin CI brief — competitive landscape report
- oxaliplatin , fluorouracil, and leucovorin updates RSS · CI watch RSS
- Sun Yat-sen University portfolio CI
Frequently asked questions about oxaliplatin , fluorouracil, and leucovorin
What is oxaliplatin , fluorouracil, and leucovorin?
How does oxaliplatin , fluorouracil, and leucovorin work?
What is oxaliplatin , fluorouracil, and leucovorin used for?
Who makes oxaliplatin , fluorouracil, and leucovorin?
What drug class is oxaliplatin , fluorouracil, and leucovorin in?
What development phase is oxaliplatin , fluorouracil, and leucovorin in?
What are the side effects of oxaliplatin , fluorouracil, and leucovorin?
What does oxaliplatin , fluorouracil, and leucovorin target?
Related
- Drug class: All Platinum-based chemotherapeutic agent and thymidylate synthase inhibitor drugs
- Target: All drugs targeting Thymidylate synthase
- Manufacturer: Sun Yat-sen University — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Adjuvant treatment of stage III colon cancer
- Indication: Drugs for First-line treatment of metastatic colorectal cancer
- Compare: oxaliplatin , fluorouracil, and leucovorin vs similar drugs
- Pricing: oxaliplatin , fluorouracil, and leucovorin cost, discount & access